Aesthetics

Billed by Editor-in-Chief John S. Rhee as “the best of both worlds,” the first issue of Facial Plastic Surgery & Aesthetic Medicine offers free access to content for a limited time.

Cosmetic physician Tahl Humes, D.O., offers recommendations for doctors who are considering investing in body toning devices. 

In this weekly report, we curate a list of consumer media articles on aesthetic topics to keep you up-to-date with what your patients are reading. Here is the March 3 edition:

Rapid Acoustic Pulse (RAP) is FDA cleared as an adjunct to treat tattoo removal — cellulite could be next.

Dr. Mark Mandell-Brown, President of AACS, details Day 3 from the Annual Scientific Meeting of the American Academy of Cosmetic Surgery. Highlights include complications from face- and neck-lifts and stem cell research.

Dr. Mike Nayak discusses the need for the internal neck anatomy to reflect the desired external result.

Dr. Angelo Cuzalina shares three face- and neck-lifting complications and solutions.

Dr. Joe Niamtu discusses his facelift experience highlighting safety, efficacy and happy patients.

Dr. Walter Tom details Day 2 from AACS 2020.

Dr. Sheila Barbarino details Day 1 from AACS 2020.

How does an aesthetic practice decide whether to invest in body toning technologies? We asked several aesthetic physicians to share what they’ve learned about what differentiates the technologies and more.

In this weekly report, we curate a list of consumer media articles on aesthetic topics to keep you up-to-date with what your patients are reading. Here is the Feb. 24 edition:

“Explain [to patients] that even though the energy device may not deliver this huge ‘wow’ factor immediately, it will likely enhance results from injectables without creating the unnatural look of high-dose injectables.” Dr. Jegasothy, M.D., Miami Skin Institute.

Dr. Jegasothy explains how she tackles the decision of which combination therapy will result in the best possible outcome for her patients. According to her, it depends on multiple factors.

The subtle results of long-wavelength devices combined with the more dramatic results of injectables can last for years and deliver more natural results than those of injectables alone.

Dr. Capi Wever discusses the prevalence of BDD in aesthetics, how to identify the psychological disorder and what to do if you discover you’ve treated a patient with BDD.

AACS will be hosting its inaugural “Women in Cosmetic Surgery Breakfast” at this year’s scientific meeting, with nine women panelists discussing the unique challenges they’ve faced and offering advice for women beginning careers in the aesthetic space.

Understanding differences among preparations and dilutions of botulinum toxin type A can improve clinical practice, according to industry experts.

In this weekly report, we curate a list of consumer media articles on aesthetic topics to keep you up-to-date with what your patients are reading. Here is the Feb. 17 edition:

Collective results from the SAKURA phase 3 clinical trial program investigating daxibotulinumtoxinA for injection for the treatment of moderate-to-severe glabellar lines show that the neuromodulator provides generally safe and long-lasting results.

Anti-aging treatments should begin sooner than later in menopausal patients, but do you know how to identify premature and early menopause? (Your patients don’t.)

According to Dr. Joe Niamtu III, knowing when to treat, when not to treat, and when to refer are all virtues of prudent injectors, regardless of specialty, seniority or type of practice.

It’s known that combination therapies can be used to create ideal treatment outcomes, but according to Dr. Suneel Chilukuri, results may also last longer than originally thought.

In this weekly report, we curate a list of consumer media articles on aesthetic topics to keep you up-to-date with what your patients are reading.

“The Aesthetic Authority has arrived. It is quite simply the first 'true' multi-specialty aesthetic publication that is created by and designed for today's aesthetic practitioners. The goal is to provide useful information and tips and pearls that will help all of us in our practices.” ⏤Dr. Randolph Waldman.

An analysis by Vanguard Communications suggests more weight is attached to physician patient reviews compared to those of hotels and restaurants.

Revance Therapeutics announces BLA acceptance for their long-acting neuromodulator, DaxibotulinumtoxinA (DAXI), with an action date set for November 25, 2020.